MedTrace Logo

Role of Saffron and Chamomile in the Management of Parkinson's Disease

NCT05696665 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-01-25

No results posted yet for this study

Summary

In multitudinous preclinical studies, Saffron and Chamomile are found effective in treating PD. They can mitigate the neurodegenerative progression of the disease by curtailing dopaminergic and neuronal loss and by inhibiting alpha-synuclein aggregation. They also possess antioxidant and anti-inflammatory activities. The synergism of both drugs can manage Parkinson's disease and related neurological disorders although, clinical trials are needed for further elaboration. Therefore, the purpose of the study is to evaluate the effects of Saffron and Chamomile and their active compounds in treating Parkinson's disease. This combination may change psychometric measures (MDS-Unified Parkinson's Disease Rating Scale), biomarkers (including Alpha-synuclein), and oxidative stress-related to Parkinson's disease. This combination along with conventional therapy might be beneficial in managing patients with Parkinson's disease

Conditions

Interventions

OTHER

conventional therapy

Patients will be kept on conventional therapy and no added drugs will be given

DRUG

Saffron and Chamomile

Patients will be given saffron and chamomile in capsule formulation twice daily

DRUG

Crocin and Apigenin

Active ingredients of saffron(Crocin) and Chamomile(Apigenin) will be given in capsule formultaion once daily

Sponsors & Collaborators

  • Aga Khan University Hospital, Pakistan

    collaborator OTHER

  • Liaquat National Hospital & Medical College

    collaborator OTHER

  • Jinnah Postgraduate Medical Centre

    lead OTHER_GOV

Principal Investigators

  • Fizzah Ali, MBBS,MPhil · Liaquat National hospital and Medical college

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-05
Primary Completion
2023-07-31
Completion
2023-07-31

Countries

  • Pakistan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05696665 on ClinicalTrials.gov